Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins.

[1]  A. Zlotnik.  Chemokines and cancer , 2006, International journal of cancer.

[2]  M. Mack,et al.  Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System , 2004, The Journal of Immunology.

[3]  T. Handel,et al.  Identification of the Glycosaminoglycan Binding Site of the CC Chemokine, MCP-1 , 2004, Journal of Biological Chemistry.

[4]  T. Kita,et al.  Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.

[5]  Mei Bai,et al.  Dimerization of G-protein-coupled receptors: roles in signal transduction. , 2004, Cellular signalling.

[6]  Alfonso Valencia,et al.  Identification of amino acid residues crucial for chemokine receptor dimerization , 2004, Nature Immunology.

[7]  Gerda E Breitwieser,et al.  G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. , 2004, Circulation research.

[8]  M. Bouvier,et al.  Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.

[9]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[10]  M. Stone,et al.  Soluble mimics of a chemokine receptor: Chemokine binding by receptor elements juxtaposed on a soluble scaffold , 2003, Protein science : a publication of the Protein Society.

[11]  T. Williams,et al.  Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi‐step model of ligand binding and receptor activation , 2003, European journal of immunology.

[12]  U. Höpken,et al.  The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity , 2003, Immunological reviews.

[13]  A. Zlotnik,et al.  Therapeutic applications in the chemokine superfamily. , 2003, Current opinion in chemical biology.

[14]  M. Uguccioni,et al.  Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. , 2003, Blood.

[15]  R. Alon,et al.  Chemokine Induction of Integrin Adhesiveness on Rolling and Arrested Leukocytes Local Signaling Events or Global Stepwise Activation? , 2003, Microcirculation.

[16]  P. Debré,et al.  Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines , 2003, Journal of Virology.

[17]  Santa Jeremy Ono,et al.  Chemokines: roles in leukocyte development, trafficking, and effector function. , 2003, The Journal of allergy and clinical immunology.

[18]  G. J. Swaminathan,et al.  Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. , 2003, Structure.

[19]  R. Horuk,et al.  Development and evaluation of pharmacological agents targeting chemokine receptors. , 2003, Methods.

[20]  J. Kirby,et al.  Chemokines and breast cancer: a gateway to revolutionary targeted cancer treatments? , 2003, Current medicinal chemistry.

[21]  K. Egashira.  Molecular Mechanisms Mediating Inflammation in Vascular Disease: Special Reference to Monocyte Chemoattractant Protein-1 , 2003, Hypertension.

[22]  M. Giacca,et al.  HIV Tat, its TARgets and the control of viral gene expression. , 2003, FEMS microbiology letters.

[23]  R. Horuk,et al.  Structure Function Differences in Nonpeptide CCR1 Antagonists for Human and Mouse CCR1 , 2003, The Journal of Immunology.

[24]  Marc Parmentier,et al.  The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.

[25]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Sinigaglia,et al.  Chemokine receptors in inflammation: an overview. , 2003, Journal of immunological methods.

[27]  R. Langer,et al.  Rational design of low-molecular weight heparins with improved in vivo activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Loetscher,et al.  Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its Ligands* , 2003, The Journal of Biological Chemistry.

[29]  A. Alcamí,et al.  Disruption of CCL21-Induced Chemotaxis In Vitro and In Vivo by M3, a Chemokine-Binding Protein Encoded by Murine Gammaherpesvirus 68 , 2003, Journal of Virology.

[30]  L. Gardner,et al.  Leukocyte extravasation: chemokine transport and presentation by the endothelium. , 2002, Blood.

[31]  Tracy M. Handel,et al.  Structural Basis of Chemokine Sequestration by a Herpesvirus Decoy Receptor , 2002, Cell.

[32]  A. Ben-Baruch.  Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions , 2002, Breast Cancer Research.

[33]  D. Hoover,et al.  The Structure of Human Macrophage Inflammatory Protein-3α/CCL20 , 2002, The Journal of Biological Chemistry.

[34]  M. Wadhwa,et al.  Chemokine/chemokine receptor nomenclature. , 2002, Journal of immunological methods.

[35]  R. Horuk,et al.  Chemokines, chemokine receptors and small-molecule antagonists: recent developments. , 2002, Trends in pharmacological sciences.

[36]  J. Galzi,et al.  Identification of the extracellular loop 2 as the point of interaction between the N terminus of the chemokine MIP-1alpha and its CCR1 receptor. , 2002, Molecular pharmacology.

[37]  S. Stringer,et al.  Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. , 2002, Blood.

[38]  B. Sykes,et al.  The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. , 2002, Biochemistry.

[39]  M. Farzan,et al.  The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1α Association and HIV-1 Entry* , 2002, The Journal of Biological Chemistry.

[40]  C. Martínez-A,et al.  Analysis of G-protein-coupled receptor dimerization following chemokine signaling. , 2002, Methods.

[41]  Klaus Ley,et al.  Chemokines and chemokine receptors in leukocyte trafficking. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[42]  Zachary Shriver,et al.  Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.

[43]  A. Sica,et al.  Tumor-associated macrophages: a molecular perspective. , 2002, International immunopharmacology.

[44]  S. Alam,et al.  CX3CR1 Tyrosine Sulfation Enhances Fractalkine-induced Cell Adhesion* , 2002, The Journal of Biological Chemistry.

[45]  C. Caux,et al.  Chemokines in cancer. , 2002, Cytokine & growth factor reviews.

[46]  T. Strassmaier,et al.  Grafting segments from the extracellular surface of CCR5 onto a bacteriorhodopsin transmembrane scaffold confers HIV-1 coreceptor activity. , 2002, Structure.

[47]  A. Zlotnik,et al.  Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.

[48]  Z. Shriver,et al.  Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. , 2002, Seminars in thrombosis and hemostasis.

[49]  Zachary Shriver,et al.  Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. , 2002, Trends in cardiovascular medicine.

[50]  A. Proudfoot.  Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[51]  R. Linhardt,et al.  Heparin-protein interactions. , 2002, Angewandte Chemie.

[52]  T. Schwartz,et al.  Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. , 2001, The Journal of clinical investigation.

[53]  C. Martínez-A,et al.  Chemokine receptor dimerization: two are better than one. , 2001, Trends in immunology.

[54]  B. Rollins.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease. , 2001, The Journal of clinical investigation.

[55]  J. Markley,et al.  Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. , 2001, Biochemistry.

[56]  M. Baggiolini,et al.  Is Dimerization Of Chemokine Receptors Functionally Relevant? , 2001, Science's STKE.

[57]  Philip M. Murphy,et al.  Chemokines and the molecular basis of cancer metastasis. , 2001, The New England journal of medicine.

[58]  J. Laurence,et al.  Structural comparison of monomeric variants of the chemokine MIP-1beta having differing ability to bind the receptor CCR5. , 2001, Biochemistry.

[59]  M. Baggiolini.  Chemokines in pathology and medicine , 2001, Journal of internal medicine.

[60]  Á. Zaballos,et al.  NMR Solution Structure of Murine CCL20/MIP-3α, a Chemokine That Specifically Chemoattracts Immature Dendritic Cells and Lymphocytes through Its Highly Specific Interaction with the β-Chemokine Receptor CCR6* , 2001, The Journal of Biological Chemistry.

[61]  R. Bonavia,et al.  Chemokines and Their Receptors in the Central Nervous System , 2001, Frontiers in Neuroendocrinology.

[62]  M. Stone,et al.  NMR solution structure and backbone dynamics of the CC chemokine eotaxin-3. , 2001, Biochemistry.

[63]  P. Loetscher,et al.  Agonistic and antagonistic activities of chemokines , 2001, Journal of leukocyte biology.

[64]  M. Mellado,et al.  Receptor dimerization: a key step in chemokine signaling. , 2001, Cellular and molecular biology.

[65]  Mario Mellado,et al.  Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.

[66]  M. Baggiolini,et al.  Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. , 2001, Blood.

[67]  M. Krangel,et al.  Chemokines have diverse abilities to form solid phase gradients. , 2001, Clinical immunology.

[68]  T. Schwartz,et al.  Virally encoded 7TM receptors , 2001, Oncogene.

[69]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[70]  R. Gentz,et al.  Solution Structure and Dynamics of Myeloid Progenitor Inhibitory Factor-1 (MPIF-1), A Novel Monomeric CC Chemokine* , 2001, The Journal of Biological Chemistry.

[71]  M. Baggiolini,et al.  The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3* , 2001, The Journal of Biological Chemistry.

[72]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[73]  M. Thelen,et al.  Dancing to the tune of chemokines , 2001, Nature Immunology.

[74]  P. Murphy.  Viral exploitation and subversion of the immune system through chemokine mimicry , 2001, Nature Immunology.

[75]  M. Mack,et al.  Endocytosis and Recycling of the HIV Coreceptor Ccr5 , 2000, The Journal of cell biology.

[76]  C. Tacchetti,et al.  Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. , 2000, The Journal of infectious diseases.

[77]  J. Błaszczyk,et al.  Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. , 2000, Biochemistry.

[78]  T. Kawano,et al.  Monocyte Chemotactic Protein-1 Receptor CCR2B Is a Glycoprotein That Has Tyrosine Sulfation in a Conserved Extracellular N-Terminal Region , 2000, The Journal of Immunology.

[79]  P. Gray,et al.  Co‐receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands , 2000, Immunological reviews.

[80]  A. Lentsch,et al.  Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC) , 2000 .

[81]  Frank Diehl,et al.  Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.

[82]  D. Fremont,et al.  Identification of a Gammaherpesvirus Selective Chemokine Binding Protein That Inhibits Chemokine Action , 2000, Journal of Virology.

[83]  D. Hoover,et al.  The Crystal Structure of the Chemokine Domain of Fractalkine Shows a Novel Quaternary Arrangement* , 2000, The Journal of Biological Chemistry.

[84]  M. Stone,et al.  NMR solution structure and receptor peptide binding of the CC chemokine eotaxin-2. , 2000, Biochemistry.

[85]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Simi Ali,et al.  Examination of the Function of RANTES, MIP-1α, and MIP-1β following Interaction with Heparin-like Glycosaminoglycans* , 2000, The Journal of Biological Chemistry.

[87]  D. Noonan,et al.  Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. , 2000, Biochemical and biophysical research communications.

[88]  S. Goda,et al.  CX3C-Chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells Through Integrin-Dependent and -Independent Mechanisms1 , 2000, The Journal of Immunology.

[89]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[90]  K. Jarnagin,et al.  Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. , 1999, Biochemistry.

[91]  A. LiWang,et al.  The solution structure of the anti‐HIV chemokine vMIP‐II , 1999, Protein science : a publication of the Protein Society.

[92]  R. Nibbs,et al.  ESkine, a Novel β-Chemokine, Is Differentially Spliced to Produce Secretable and Nuclear Targeted Isoforms* , 1999, The Journal of Biological Chemistry.

[93]  D. Du,et al.  The N Terminus of Kaposi's Sarcoma-associated Herpesvirus G Protein-coupled Receptor Is Necessary for High Affinity Chemokine Binding but Not for Constitutive Activity* , 1999, The Journal of Biological Chemistry.

[94]  K. Jarnagin,et al.  Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. , 1999, Biochemistry.

[95]  V. Appay,et al.  Aggregation of RANTES Is Responsible for Its Inflammatory Properties , 1999, The Journal of Biological Chemistry.

[96]  R. Hubbard,et al.  Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. , 1999, Biochemistry.

[97]  K. Pillarisetti,et al.  Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. , 1999, Journal of immunology.

[98]  J. V. van Putten,et al.  Sulfated Polysaccharide-Directed Recruitment of Mammalian Host Proteins: a Novel Strategy in Microbial Pathogenesis , 1999, Infection and Immunity.

[99]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[100]  B. Rollins,et al.  Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[101]  I. Charo,et al.  Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction , 1999, The Journal of Biological Chemistry.

[102]  A. Richmond,et al.  Multiple chemotactic factors: fine control or redundancy? , 1999, Trends in pharmacological sciences.

[103]  G. McFadden,et al.  Immunomodulation by viruses: the myxoma virus story , 1999, Immunological reviews.

[104]  B. Rollins,et al.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.

[105]  Joseph Sodroski,et al.  Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry , 1999, Cell.

[106]  N. Skelton,et al.  Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. , 1999, Structure.

[107]  F. Sánchez‐Madrid,et al.  Leukocyte polarization in cell migration and immune interactions , 1999, The EMBO journal.

[108]  T M Handel,et al.  Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. , 1999, Biochemistry.

[109]  K. Jarnagin,et al.  Monomeric Monocyte Chemoattractant Protein-1 (MCP-1) Binds and Activates the MCP-1 Receptor CCR2B* , 1998, The Journal of Biological Chemistry.

[110]  R. Rabin,et al.  HIV-1 Tat protein mimicry of chemokines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  B. Sykes,et al.  Solution Structure of Eotaxin, a Chemokine That Selectively Recruits Eosinophils in Allergic Inflammation* , 1998, The Journal of Biological Chemistry.

[112]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[113]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[114]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[115]  T. Schwartz,et al.  Plagiarism of the host immune system: lessons about chemokine immunology from viruses. , 1997, Current opinion in biotechnology.

[116]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[117]  M. Auer,et al.  Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells , 1997, Cell.

[118]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[119]  I. Charo,et al.  The Amino-terminal Domain of CCR2 Is Both Necessary and Sufficient for High Affinity Binding of Monocyte Chemoattractant Protein 1 , 1997, The Journal of Biological Chemistry.

[120]  S. Stringer,et al.  Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate* , 1997, The Journal of Biological Chemistry.

[121]  N. Skelton,et al.  Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. , 1997, Biochemistry.

[122]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[123]  J. Katancik,et al.  Mapping of the extracellular binding regions of the human interleukin-8 type B receptor. , 1997, Biochemical and biophysical research communications.

[124]  T. Handel,et al.  Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. , 1997, Journal of immunology.

[125]  C. Mackay,et al.  Discrete Steps in Binding and Signaling of Interleukin-8 with Its Receptor* , 1996, The Journal of Biological Chemistry.

[126]  B. Sykes,et al.  Structural characterization of a monomeric chemokine: Monocyte chemoattractant protein‐3 , 1996, FEBS letters.

[127]  P. Domaille,et al.  Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. , 1996, Biochemistry.

[128]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[129]  T. Martin,et al.  Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis. , 1996, Biochemical and biophysical research communications.

[130]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[131]  M. Baggiolini,et al.  Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant , 1996, The Journal of experimental medicine.

[132]  M. Peitsch,et al.  Selectivity and antagonism of chemokine receptors , 1996, Journal of leukocyte biology.

[133]  B. Rollins,et al.  A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer , 1995, Molecular and cellular biology.

[134]  T. Schall,et al.  Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. , 1995, Biochemistry.

[135]  J. Navarro,et al.  The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8. , 1994, The Journal of biological chemistry.

[136]  L. Chen,et al.  Crystal structure of recombinant human platelet factor 4. , 1994, Biochemistry.

[137]  B. Dewald,et al.  Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids. , 1994, The Journal of biological chemistry.

[138]  B. Sykes,et al.  Neutrophil activation by monomeric interleukin-8 , 1994 .

[139]  D. S. Garrett,et al.  High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.

[140]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[141]  M. Baggiolini,et al.  Activation of neutrophil leukocytes: chemoattractant receptors and respiratory burst 1 , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  B. Dewald,et al.  Interleukin-8 antagonists generated by N-terminal modification. , 1993, The Journal of biological chemistry.

[143]  A. Rot.  Neutrophil attractant/activation protein‐1 (interleukin‐8) induces in vitro neutrophil migration by haptotactic mechanism , 1993, European journal of immunology.

[144]  A. Gronenborn,et al.  Three-dimensional structure of interleukin 8 in solution. , 1991, Biochemistry.

[145]  M. Baggiolini,et al.  Turning on the respiratory burst. , 1990, Trends in biochemical sciences.

[146]  T. Handel,et al.  Chemokine structure and receptor interactions. , 2004, Ernst Schering Research Foundation workshop.

[147]  D. Noonan,et al.  HIV-Tat dependent chemotaxis and invasion, key aspects of Tat mediated pathogenesis , 2004, Clinical & Experimental Metastasis.

[148]  P. Proost,et al.  Regulation of the immune response by the interaction of chemokines and proteases. , 2003, Advances in immunology.

[149]  E. Kunkel,et al.  Homeostatic chemokines and the targeting of regional immunity. , 2002, Advances in experimental medicine and biology.

[150]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[151]  K. Egashira,et al.  Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. , 2002, Journal of atherosclerosis and thrombosis.

[152]  C. Weber.  Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules , 2002, Journal of Molecular Medicine.

[153]  Z. Shriver,et al.  Direct isolation and sequencing of specific protein-binding glycosaminoglycans , 2001, Nature Medicine.

[154]  D. Noonan,et al.  From the outside in: extracellular activities of HIV Tat. , 2000, Advances in pharmacology.

[155]  J. Lubkowski,et al.  The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions , 1997, Nature Structural Biology.

[156]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[157]  T. Springer,et al.  Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. , 1995, Annual review of physiology.

[158]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[159]  B. Dewald,et al.  [Properties and activation mechanism of neutrophilic leukocytes]. , 1989, Arzneimittel-Forschung.